Jonathan W. Goldman, MD, GRACE Faculty

https://www.facebook.com/jonathan.goldman.969
Twitter Feed
GRACE Faculty, Lung Cancer
UCLA Medical Center
Santa Monica
CA
Specialties
Assistant Professor, UCLA Hematology & Oncology
Associate Director of Drug Development
Director of Clinical Trials in Thoracic Oncology
Santa Monica, CA

Dr. Jonathan Goldman is a medical oncologist on the faculty of the Lung Cancer division of GRACE. He is an Assistant Professor of UCLA Hematology and Oncology, Associate Director of Drug Development and Director of Clinical Trials in Thoracic Oncology at UCLA Medical Center in Santa Monica, California.

Medical Board Certifications -
Internal Medicine, American Board of Internal Medicine, 2004, 2017 Hematology, American Board of Internal Medicine, 2008 Medical Oncology, American Board of Internal Medicine, 2008 FellowshipHematology-Oncology, UCLA School of Medicine, 2005-2008 ResidencyUC San Francisco School of Medicine, 2002-2004 InternshipInternal Medicine, UC San Francisco School of Medicine, 2001-2002 DegreeStanford University School of Medicine, 1996

Conflict of Interest

None

Why Carboplatin, Pemetrexed and Pembrolizumab Have Become My New Go-to Regimen for First-Line Non-Squamous NSCLC Treatment
Post

Dr. Jonathan Goldman joins GRACE to explain why carboplatin, pemetrexed and pembrolizumab has become his new go-to regimen for first-line non-squamous NSCLC treatment.

Comments

test
Post Date:
Original Post: Nodule concern

test test test

test
Post Date:
Original Post: Test - forum post

test

Example Comment for Forum Post
Post Date:
Original Post: SCLC Example Post

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nullam id sapien quis lorem sollicitudin